Clinical Trials
6
Active:1
Completed:1
Trial Phases
1 Phases
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (100.0%)Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study
Not Applicable
Not yet recruiting
- Conditions
- Type 2 Diabetes MellitusType2diabetesDiabetes Mellitus, Type 2Type 2 DiabetesDiabetes
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT07197788
Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)
Not yet recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Type2DiabetesDiabetes Mellitus, Type 2Type 2 DiabetesDiabetes
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT07197775
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Not Applicable
Recruiting
- Conditions
- Diabetes Mellitus, Type 2Type 2 DiabetesDiabetesType 2 Diabetes MellitusType2diabetes
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT06267391
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Velocity Clinical Research, Gardena, Gardena, California, United States
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
Not Applicable
Active, not recruiting
- Conditions
- DiabetesMetabolic DiseaseEndocrine System DiseasesDiabetes Type 2Diabetes Mellitus, Type 2Diabetes MellitusGlucose Metabolism Disorders
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05014204
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Cuyuna Regional Medical Center, Crosby, Minnesota, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04725890
- Locations
- 🇦🇺
The BMI Clinic, Sydney, New South Wales, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
News
No news found